It is currently Tue Oct 13, 2015 12:16 am

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.


This is my first post and I don't really have a clue what I am doing! I came across this "lead-in" article on the "news for the day", i.e., current, New England Journal website. It costs $29.95 to read the entire article and I really don't want to make the investment. Perhaps some of you know what this means:

Progressive Multifocal Leukoencephalopathy, Natalizumab, and Multiple Sclerosis

To the Editor: According to the established definition of ...
Read more : Tysabri | Views : 1706 | Replies : 3


Rituximab (rituxan) is in Phase ii trials (Biogen is the drugs company behind rituxan).

The following research paper suggests it has benefits - it affects B cells (rather than the usual T cells)

Bromley ... tabil.html
Read more : Rituximab | Views : 1295 | Replies : 0

Antisense Therapeutics

Antisense Therapeutics were trialling an oral drug which targeted the same protein as Tysabri. The company stopped the trial following the Tysabri fiasco. The company has applied to restart the trial (may need to add to Dignan's list of approval given).
Read more : Antisense Therapeutics | Views : 1377 | Replies : 0

Updated Interim NeuroVax(TM) Data

New NeuroVax Data from the European MS Meeting

Read more : Updated Interim NeuroVax(TM) Data | Views : 1454 | Replies : 0


And another article which also refers to Mylinax (sp?). Still looking at 2008 or 2009 before an oral therapy is available.
Read more : FTY720 | Views : 1686 | Replies : 1


I have no idea what Padma28 is but it seems to have some benefit for chronic progressive ms sufferers.

PS I found some more information - it's a Tibetan medicine.

<shortened url>

It seems to consist of a vast range of ingredients - as our nutrition expert Melody might translate for us.
Read more : Padma28 | Views : 3664 | Replies : 2


Login  •  Register


Total posts 227795 • Total topics 24073 • Total members 15410

Contact us | Terms of Service